Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABSI, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| ABS-201 SC Multiple Doses | Androgenetic Alopecia (AGA) | Phase 1/2 · NCT07317544 | Recruiting |
| SAD IV Dose 1 - 150mg ABS201 IV Single D | Androgenetic Alopecia (AGA) | Phase 1/2 · NCT07317544 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABSI holds $299.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $26.9M/quarter from operations, an estimated runway of 33.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABSI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR, LLC | Institution (13F) | 22,382,002 | 13.04% | 2025-12-31 |
| ARK Investment Management, LLC | Institution (13F) | 12,550,799 | 7.31% | 2025-12-31 |
| Blackrock Inc. | Institution (13F) | 11,333,432 | 6.60% | 2025-12-31 |
| Sean McClain Chief Executive Officer, Director · +3.21M options |
Insider | 8,655,555 | 5.04% | 2026-06-24 |
| Redmile Group, LLC | Institution (13F) | 8,253,316 | 4.81% | 2025-12-31 |
| Vanguard Group Inc | Institution (13F) | 7,910,205 | 4.61% | 2025-12-31 |
| State Street Corporation | Institution (13F) | 5,990,877 | 3.49% | 2025-12-31 |
| Advanced Micro Devices Inc | Institution (13F) | 5,714,285 | 3.33% | 2025-12-31 |
| Geode Capital Management, LLC | Institution (13F) | 3,239,623 | 1.89% | 2025-12-31 |
| Ameriprise Financial, Inc. | Institution (13F) | 3,196,577 | 1.86% | 2025-12-31 |
| UBS Group AG | Institution (13F) | 2,699,505 | 1.57% | 2025-12-31 |
| Zachariah Jonasson CFO / CBO · +1.07M options |
Insider | 483,144 | 0.28% | 2026-08-31 |
Share count 171,614,010 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-31 filed 2026-09-01 |
Jonasson Zachariah |
Tax withholding (F) | 8,320 | $8.71 | 483,144 |
| 2026-08-03 filed 2026-08-07 |
Somaratne Ransi Mudalinayake |
Option award (A) | 383,000 | – | – |
| 2026-03-03 filed 2026-08-07 |
Somaratne Ransi Mudalinayake |
Option award (A) | 650,000 | – | – |
| 2026-06-30 filed 2026-07-06 |
Szela Mary T |
Purchase (P) | 12,900 | $11.54 | 21,300 |
| 2026-06-24 filed 2026-06-26 |
McClain Sean |
Tax withholding (F) | 59,896 | $10.08 | 8,655,555 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABSI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →